2025-11-15 - Analysis Report
Okay, let's break down this analysis of Merck & Co Inc (MRK).

## Merck & Co Inc (MRK) Analysis

**Ticker:** MRK
**Company Description:** Merck & Co Inc is a global pharmaceutical company that discovers, develops, manufactures, and markets a wide range of healthcare products.

### 1.  Performance Relative to S&P 500 (VOO)

**Key Numbers:**

*   **MRK Cumulative Return:** 9.79%
*   **VOO Cumulative Return:** 98.45%
*   **Spread (MRK - VOO):** -88.66%
*   **Spread Range:** Max: 23.9, Min: -104.3, Current: -99.8
*   **Relative Spread Position:** 3.5

**Analysis:**

MRK has significantly underperformed the S&P 500 (VOO) over the period. The current difference in cumulative return is substantial. The relative spread position of 3.5 indicates that MRK's underperformance, relative to VOO, is near its historical worst within the analyzed period.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
| ---------- | ------ | ------ | ------ | ---- | ------ |
| 2015-2017  | 1.0%   | 68.5%  | -27.0% | 0.2  | 133.3  |
| 2016-2018  | 36.0%  | 69.8%  | 21.0%  | 0.3  | 181.0  |
| 2017-2019  | 40.0%  | 69.8%  | 18.0%  | 0.3  | 215.4  |
| 2018-2020  | 16.0%  | 79.6%  | -8.0%  | 0.3  | 193.8  |
| 2019-2021  | 2.0%   | 79.6%  | -44.0% | 0.7  | 190.2  |
| 2020-2022  | 15.0%  | 79.6%  | 16.0%  | 0.7  | 275.4  |
| 2021-2023  | 33.0%  | 79.6%  | 31.0%  | 0.3  | 270.6  |
| 2022-2024  | -4.0%  | 79.6%  | -25.0% | 0.2  | 246.9  |
| 2023-2025  | -39.0% | 71.5%  | -102.0%| 1.8  | 230.7  |

**Analysis:**

*   **CAGR:** Fluctuates significantly, with recent periods showing negative growth.
*   **MDD:** High Maximum Drawdown indicates significant volatility and potential for large losses.
*   **Alpha:**  Alpha is inconsistent, ranging from highly negative to positive, indicating inconsistent outperformance relative to the market. The most recent period shows a very negative alpha.
*   **Beta:** Beta values are generally low, suggesting MRK is less sensitive to market movements than the S&P 500, except for the 2023-2025 period with a beta of 1.8.

### 2.  Recent Stock Price Movements

**Key Numbers:**

*   **Current Price:** 92.92
*   **Previous Close:** 92.93
*   **Change:** -0.01
*   **5-Day Moving Average:** 91.0
*   **20-Day Moving Average:** 87.4027
*   **60-Day Moving Average:** 85.154

**Analysis:**

The stock price is trading slightly below its previous close. The 5-day moving average is above the 20-day and 60-day moving averages, which suggests a short-term upward trend.

### 3.  Technical Indicators

**Key Numbers:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 65.41
*   **PPO:** 0.861
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (11 shares - Very Safe - MRI:0.90)
*   **Recent Relative Divergence Change (20-day):** 1.6 (+) (Short-term Increase)
*   **Expected Return:** -209.8%

**Analysis:**

*   **MRI:** Indicates a medium level of investment risk.
*   **RSI:**  At 65.41, RSI suggests the stock is approaching overbought territory, but not yet at extreme levels.
*   **PPO:** Positive PPO indicates that the short-term moving average is above the long-term moving average, suggesting a bullish trend.
*   **Hybrid Signal:**  Recommends a full investment of available cash, indicating a bullish signal based on the algorithm.
*   **Relative Divergence Change:** Short-term increase indicates positive momentum.
*   **Expected Return:** A very negative expected return suggests potential long-term underperformance compared to the S&P 500.
* **Price Change:** The negligible change between the price and the previous close suggests no significant price volatility at the very end of the period.

### 4.  Recent News & Significant Events

*   **Merck Acquires Cidara Therapeutics:** A $9.2 Billion deal indicates strategic expansion and potential for new revenue streams.
*   **Sector Update: Health Care Stocks Ease Late Afternoon:** This suggests a broader market trend that could be influencing MRK.
*   **Biotech Stock Doubles:** While not directly related to MRK, it highlights the potential for significant gains in the biotech sector.
*   **RedChip Congratulates Cidara:** Further confirmation of the acquisition.

**Analysis:**

The acquisition of Cidara Therapeutics is a significant event that could positively impact MRK's future performance. However, broader market trends in the healthcare sector should be considered.

### 4-2. Analyst Opinions

**Analysis:**

*   **Consensus:** The average analyst rating is a 'Buy' with a mean rating of 2.00, suggesting positive sentiment.
*   **Target Price:** The average target price of $102.32 suggests potential upside from the current price. However, there is a wide range of target prices (high: $137.00, low: $82.00), indicating uncertainty among analysts.
*   **Recent Rating Changes:** Lack of recent changes suggests a stable outlook from analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
| ---------- | ---- | ----------- |
| 2025-11-05 | 2.32 | 17.28 B$    |
| 2025-08-05 | 1.76 | 15.81 B$    |
| 2025-05-02 | 2.01 | 15.53 B$    |
| 2024-11-06 | 1.25 | 16.66 B$    |
| 2025-11-05 | 1.25 | 16.66 B$    |

**Analysis:**
The company's most recent EPS of 2.32 and revenue of $17.28B show growth compared to previous quarters and the previous year. This could be seen as a positive sign for the company's financial health.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
| ------------ | ----------- | ------------- |
| 2025-09-30   | $17.28B     | 77.69%        |
| 2025-06-30   | $15.81B     | 77.50%        |
| 2025-03-31   | $15.53B     | 77.98%        |
| 2024-12-31   | $15.62B     | 75.50%        |
| 2024-09-30   | $16.66B     | 75.51%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE     |
| ------------ | ----------- | ------- |
| 2025-09-30   | $51.85B     | 11.16%  |
| 2025-06-30   | $48.99B     | 9.04%   |
| 2025-03-31   | $48.34B     | 10.51%  |
| 2024-12-31   | $46.31B     | 8.08%   |
| 2024-09-30   | $44.50B     | 7.09%   |

**Analysis:**

*   **Revenue:** Shows an increasing trend over the past few quarters.
*   **Profit Margin:**  Consistently high profit margins, indicating strong pricing power and efficient cost management.
*   **Equity:**  Equity is steadily increasing, suggesting a healthy balance sheet.
*   **ROE:** Return on Equity is also increasing, indicating improved profitability for shareholders.

### 7. Summary Analysis

*   **Underperformance:** MRK has significantly underperformed the S&P 500.
*   **Recent Positive Momentum:** Recent short-term price movements and positive analyst ratings suggest potential for near-term gains.
*   **Strong Financials:** Revenue, profit margins, and ROE are generally trending positively.
*   **Acquisition:** The acquisition of Cidara Therapeutics is a potential catalyst for future growth.
*   **MRI:**  Medium risk investment profile.
*   **Long-Term Concerns:** The very negative expected return raises concerns about long-term underperformance relative to the market.

**Overall, the analysis presents a mixed picture.** While recent positive trends and the Cidara Therapeutics acquisition are encouraging, the significant underperformance relative to the S&P 500 and the negative expected return are major concerns. Investors should carefully consider their risk tolerance and investment horizon before making a decision. The hybrid signal recommending a buy suggests the model sees value, but the negative expected return tempers enthusiasm.
